New hope for Alzheimer's sufferers from Leipzig

A large team led by Prof. Dr Dorothee Saur has spent months setting up the complex processes and organising interdisciplinary collaboration between the neurology, neuroradiology and nuclear medicine departments. The patient now receives an infusion every fortnight and is closely monitored with MRI and PET in order to precisely track the effect and possible reactions in the brain. The aim is to visibly reduce pathological amyloid deposits and maintain the patient's ability to carry out everyday activities for as long as possible. The therapy is still only suitable for a small group, but interest is huge. Around fifty people a week contact the dementia consultation centre to have their chances assessed. With donanemab, a second active substance is already available that is also suitable for early stages. Experts are expecting further progress and are hoping for a turning point for many sufferers and their families.